Product Information
DOVATO 50-300 MG TABLET is a brand product labeled by ViiV Healthcare Company, priced at $105.2246 per EA under NDC 49702024613. Its NADAC has been published 368 times since Sep 18, 2019.
FDA first approved this application on Apr 8, 2019.
Strength
50; 300 mg/1; mg/1
Manufacturer
ViiV Healthcare CompanyNDC
49702024613
Classification
Brand
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
DOLUTEGRAVIR SODIUM; LAMIVUDINEApproval Type
New Drug (NDA)
FDA Application
NDA211994FDA Approved
4/8/2019
On Market Since
4/8/2019
Pharmacological Classes
Price Statistics
The NADAC for DOVATO 50-300 MG TABLET has been published 368 times since Sep 18, 2019, and over the history we have for it it has risen 42.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $105.2246 per EA |
|---|---|
| All-time high | $105.2874 (May 13, 2026) |
| All-time low | $74.0751 (Sep 18, 2019) |
| 52-week high | $105.2874 |
| 52-week low | $99.9590 |
| Median price | $90.6881 |
| Average price | $89.6653 |
| Largest weekly change | +5.9% (Jan 11, 2023) |
| Weeks tracked | 368 |
| Tracking since | Sep 18, 2019 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
ViiV Healthcare Company manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
dolutegravir sodium and lamivudine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of DOVATO 50-300 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for DOVATO 50-300 MG TABLET, manufactured by ViiV Healthcare Company, is $105.2246 per EA (NDC 49702024613), effective Sep 30, 2026.
How has the price of DOVATO 50-300 MG TABLET changed over time?
Over the history we have for it, the NADAC for DOVATO 50-300 MG TABLET has risen 42.1%. It has been tracked across 368 weekly CMS publications since Sep 18, 2019.
What are the highest and lowest recorded NADAC prices for DOVATO 50-300 MG TABLET?
Since Sep 18, 2019, the NADAC for DOVATO 50-300 MG TABLET has ranged from a low of $74.0751 (Sep 18, 2019) to a high of $105.2874 (May 13, 2026), with a median of $90.6881 per EA.
Are there cheaper alternatives to DOVATO 50-300 MG TABLET?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as DOVATO 50-300 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures DOVATO 50-300 MG TABLET?
DOVATO 50-300 MG TABLET (NDC 49702024613) is labeled by ViiV Healthcare Company, and CMS classifies it as a brand product.